|
Name |
4-Chlorocinnamamide
|
Molecular Formula | C9H8ClNO | |
IUPAC Name* |
(E)-3-(4-chlorophenyl)prop-2-enamide
|
|
SMILES |
C1=CC(=CC=C1/C=C/C(=O)N)Cl
|
|
InChI |
InChI=1S/C9H8ClNO/c10-8-4-1-7(2-5-8)3-6-9(11)12/h1-6H,(H2,11,12)/b6-3+
|
|
InChIKey |
PWXPFYVNYKVJBW-ZZXKWVIFSA-N
|
|
Synonyms |
4-Chlorocinnamamide; 18166-64-8; p-Chlorocinnamamide; 3-(4-Chlorophenyl)acrylamide; (2E)-3-(4-Chlorophenyl)-2-propenamide; 3-(4-chlorophenyl)prop-2-enamide; 2-Propenamide, 3-(4-chlorophenyl)-; p-Chlorocinnamide; (E)-3-(4-chlorophenyl)prop-2-enamide; (2E)-3-(4-chlorophenyl)prop-2-enamide; 4-Chlorocinnamide,trans; 4-Chlorobenzeneacrylamide; 4-Chlorocinnamamide, 97%; SCHEMBL8147578; ZINC156277; (E)-3-(4-Chlorophenyl)acrylamide; (2e)-3-(4-chlorophenyl)acrylamide; MFCD00017147; STL497885; AKOS002969818; AKOS037645662; AS-62026; (2E)-3-(4-Chlorophenyl)-2-propenamide #; 166C648
|
|
CAS | NA | |
PubChem CID | 5364144 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 181.62 | ALogp: | 1.8 |
HBD: | 1 | HBA: | 1 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 43.1 | Aromatic Rings: | 1 |
Heavy Atoms: | 12 | QED Weighted: | 0.7 |
Caco-2 Permeability: | -4.48 | MDCK Permeability: | 0.00002870 |
Pgp-inhibitor: | 0.826 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.003 |
30% Bioavailability (F30%): | 0.002 |
Blood-Brain-Barrier Penetration (BBB): | 0.997 | Plasma Protein Binding (PPB): | 90.45% |
Volume Distribution (VD): | 0.704 | Fu: | 8.68% |
CYP1A2-inhibitor: | 0.979 | CYP1A2-substrate: | 0.722 |
CYP2C19-inhibitor: | 0.45 | CYP2C19-substrate: | 0.069 |
CYP2C9-inhibitor: | 0.076 | CYP2C9-substrate: | 0.786 |
CYP2D6-inhibitor: | 0.539 | CYP2D6-substrate: | 0.651 |
CYP3A4-inhibitor: | 0.023 | CYP3A4-substrate: | 0.231 |
Clearance (CL): | 7.089 | Half-life (T1/2): | 0.289 |
hERG Blockers: | 0.241 | Human Hepatotoxicity (H-HT): | 0.111 |
Drug-inuced Liver Injury (DILI): | 0.841 | AMES Toxicity: | 0.324 |
Rat Oral Acute Toxicity: | 0.044 | Maximum Recommended Daily Dose: | 0.043 |
Skin Sensitization: | 0.711 | Carcinogencity: | 0.594 |
Eye Corrosion: | 0.122 | Eye Irritation: | 0.979 |
Respiratory Toxicity: | 0.04 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001420 | 0.500 | D01AJY | 0.392 | ||||
ENC001441 | 0.468 | D0VB0U | 0.375 | ||||
ENC001578 | 0.415 | D0C7AA | 0.367 | ||||
ENC001510 | 0.404 | D01ZJK | 0.362 | ||||
ENC001854 | 0.367 | D06CDO | 0.347 | ||||
ENC001460 | 0.362 | D0J5DC | 0.333 | ||||
ENC001091 | 0.362 | D0V9EN | 0.333 | ||||
ENC000005 | 0.349 | D0P8RS | 0.317 | ||||
ENC001440 | 0.333 | D00BCP | 0.317 | ||||
ENC000665 | 0.333 | D01ZSO | 0.288 |